Publications by authors named "Annelore Cortoos"

Claim this Profile
P
Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma.
Matthew J Pianko, Niodita Gupta-Werner, Bruno Emond, Patrick Lefebvre, Marie-Hélène Lafeuille, Annelore Cortoos

Future Sci OA· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the Editor regarding 'Evaluating nurse preferences for a novel on-body delivery system vs. manual syringes for large-volume subcutaneous drug administration: a survey study'.
Rohan Medhekar, Laura Clark, Santosh Gautam, Annelore Cortoos

Drug Deliv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS.
Paula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, Jacob Laubach, Hermann Einsele, Annelore Cortoos

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses.
Laahn Foster, Larry D Anderson, Alfred Chung, Chakra P Chaulagain, Erin Pettijohn, Annelore Cortoos

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma.
Lucio N Gordan, Amanda Warner, Trevor Heritage, Amy Ming, Niodita Gupta-Werner, Annelore Cortoos

Future Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
Meletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, Yael C Cohen, Vania Hungria, Annelore Cortoos

N Engl J Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.
Ashraf Badros, Laahn Foster, Larry D Anderson, Chakra P Chaulagain, Erin Pettijohn, Annelore Cortoos

Blood· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.
Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Annelore Cortoos

Future Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma.
Doris K Hansen, Santosh Gautam, Marie-Hélène Lafeuille, Carmine Rossi, Bronwyn Moore, Annelore Cortoos

Cancer Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Rebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, Douglas W Sborov, Brandi Reeves, Annelore Cortoos

Am J Hematol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.
Ajai Chari, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Annelore Cortoos

Blood Cancer J· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Annelore Cortoos

Br J Haematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Natalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, Kelly N Godby, Jacob Laubach, Annelore Cortoos

Blood Cancer J· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Annelore Cortoos

Lancet Haematol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
Saurabh Chhabra, Natalie Callander, Nicole L Watts, Luciano J Costa, Bicky Thapa, Annelore Cortoos

Transplant Cell Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Annelore Cortoos

Future Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Douglas W Sborov, Muhamed Baljevic, Brandi Reeves, Jacob Laubach, Yvonne A Efebera, Annelore Cortoos

Br J Haematol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.
Andrzej J Jakubowiak, Shaji Kumar, Rohan Medhekar, Huiling Pei, Patrick Lefebvre, Annelore Cortoos

Oncologist· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Annelore Cortoos

Blood Cancer J· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.
Ali T Taher, Raffaella Origa, Silverio Perrotta, Alexandra Kourakli, Giovan Battista Ruffo, Annelore Cortoos

Am J Hematol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis